newsfilter
← Latest News
GlobeNewswire·

Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

EVAX
  • Three-year data from the EVX-01 phase 2 trial in advanced melanoma patients demonstrates an immune response in all participants, with 89% of vaccine neoantigens generating potent specific T-cell responses.
  • Sustained T-cell responses were observed during the third year of EVX-01 monotherapy, maintaining both the magnitude & breadth of the specific immune response.
  • All patients maintained their clinical response from the two-year follow-up with no tumor progression observed through the third year of treatment.
  • The new findings supplement two-year data which showed a 75% Objective Response Rate, 25% complete response rate, 92% of patients still responding, & no relapses.
  • 54% of patients achieved a deepened response following treatment initiation, improving from stable disease or partial response to partial or complete response.
  • Tumor reduction in target lesions was observed in 15 out of the 16 patients enrolled in the trial.
  • The initial two-year treatment phase involved EVX-01 combined with MSD's KEYTRUDA, while six of the twelve responders continued in a one-year extension receiving EVX-01 as stand-alone therapy.
  • Evaxion A/S announces a cash runway extending well into the second half of 2027.
  • Data will be presented at the ESMO 2026 Congress in Madrid on October 24, 2026, followed by a webinar featuring Professor Muhammad Adnan Khattak on October 29, 2026.
  • EVX-01 is a personalized peptide-based cancer vaccine designed using the AI-Immunology™ platform to target unique tumor profiles in patients with advanced melanoma.